FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Search
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Candice is moving to Germany
Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
From the archives: Maria Plum’s story as a pioneer of her time
Maria Plum was one of the first female lawyers in Germany, and she served as legal counselor for our company starting in the 1930s. Read account of her story written by Katrin Lege, Head of the Boehringer Ingelheim Company Archives, who discovered details
Emerging Talent
At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Post-Traumatic Stress Disorder | PDF | Boehringer Ingelheim US
Jentadueto XR® Medication Guide | PDF | Boehringer Ingelheim US
Digital solutions save lives
Digital solutions save lives
How to Apply
To apply for the program, please complete one of the following application forms and follow the directions on the application form submission
Commercial
Commercial
Looking Ahead at Recruitment in the Biopharma Industry
Looking Ahead at Recruitment in the Biopharma Industry
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Cafeteria Crews Cook for Community | Boehringer Ingelheim US
Read more on how BI cafeteria crews are supporting their communities by cooking over 500 meals a day for first responders & others during the pandemic.
The power of patient advocacy in cancer care
Patients and advocacy organizations agree that patient empowerment is key to quality cancer care
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline